Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib in Advanced Gastrointestinal Tumors (Observational Safety and Efficacy Study)
ChiCTR2200057717Phase 4Not yet recruiting
- Sponsor
- Anqing Hospital of the PLA Navy
- Start
- Mar 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of surufatinib in gastrointestinal stromal tumor (GIST), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 4 more, sponsored by Anqing Hospital of the PLA Navy. Primary endpoint: progression-free survival. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
surufatinib
03
Conditions
gastrointestinal stromal tumor (GIST)gastric adenocarcinomagastroesophageal junction adenocarcinomacolorectal cancer (CRC)biliary cancer
Beyond the preview
Go deeper on ChiCTR2200057717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057717.